Comparing Bendamustine-Based Bridging to Standard Chemotherapy in CAR T Cell Therapy for Multiple Myeloma: An Analysis of Toxicity Profiles
Multiple myeloma (MM) remains an incurable malignancy arising from plasma cells, however great promise has been seen with the use of Chimeric Antigen Receptor (CAR) T cells. Autologous CAR-T products require bridging therapy, however little is known about different agents used in this manner. Some studies indicate decrease in disease burden is crucial, while others note an association with higher rates of toxicity and negative effect on survival. As commercial CAR T cell therapy is indicated after failure of at least 4 prior treatments, careful consideration of bridging therapy is crucial, particularly in patients with agg...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Yan Leyfman, Sridevi Rajeeve, Tianxiang Sheng, Marcio Diniz, Shambavi Richard, Sundar Jagannath, Adriana Rossi Tags: 530 Source Type: research
Contemporary Treatment Options Beyond Chimeric Antigen Receptor (CAR) T-Cell Therapies for Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): A Systematic Literature Review (SLR)
Refractory or relapsed large B-cell lymphoma (R/R LBCL) remains a significant challenge for patients (Coiffier et al. Blood. 2010). Chimeric antigen receptor (CAR) T-cell therapy has emerged as standard of care for most patients with R/R LBCL after receiving the initial line of treatment (Dreger et al. Blood Adv. 2020). Other therapies with different mechanisms of action also received regulatory approvals as second or third line (2L or 3L) treatment in recent years. We performed an SLR to understand the efficacy and real-world (RW) effectiveness of non –CAR T-cell therapies for R/R LBCL including tafasitamab with lenalid...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Matthew Lunning, Christopher Dieyi, Polly Field, Zhen-Huan Hu, Marta Radwan, Harry Miao, Fang Sun, Christine Fu, Clare Spooner, Marcelo C. Pasquini Tags: 493 Source Type: research
Post Transplant Bendamustine Partially Replacing Cyclophosphamide As Gvhd Prophylaxis in T Cell Replete Haploidentical Stem Cell Transplantation-Single Center Experience
Post –transplant cyclopshophamide (PTCy) is the commonly applied graft-versus-host disease (GVHD) prophylaxis regimen in T cell replete haplo-stem cell transplantation. Although PT-CY attained great success in HaploSCT arena to prevent GVHD but complicated with higher incidence of Veno-occlusive diseas e (VOD) and infections. To mitigate these we have attempted a different approach, replacing the Day+4 PTCy with Bendamustine (PT-BEN). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Joydeep Chakrabartty, Arijit Bishnu, Akash Bhojgaria, Mihir Das, Sara Panmei, Ranjith Kumar CS, Amrita Chakravarti Tags: 412 Source Type: research
Bendamustine-Containing Regimens before CAR T-Cell Therapy Have Detrimental Effect on Progression-Free Survival
Chimeric antigen receptor T (CAR-T) cell therapy has become widely used in patients with relapsed and refractory B-cell lymphomas and considered the standard of care in such patients. The success of CAR-T cell therapy depends on the number and fitness of the autologous T-cells used during the manufacturing phase. Patients who received bendamustine prior to CAR-T cell therapy may experience higher incidence of failure of CAR-T given its known lymphotoxic effects and thus toxic effects on circulating T-cells. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Zena Chahine, Kara Fields, Mahmoud Amr, Donglin Yan, Reshma Ramlal, Gregory Monohan, Reinhold Munker, Fevzi Yalniz, Ayman Qasrawi, Chaitanya Iragavarapu Tags: 289 Source Type: research
Outcome Analysis in Patients with Hematologic Malignancies Following Bendamustine Lymphodepletion Preceding CAR-T Cell Therapy.
CAR-T therapy is a transformative treatment for adult patients with relapsed or refractory (r/r) non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). Traditionally, the lymphodepletion (LD) approach relied on fludarabine and cyclophosphamide (flu/cy). A shortage of fludarabine has led to a paradigm shift towards alternative LD agents. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Ilias Christodoulou, Kristine Cooper, Warren Shlomchik, Kathleen Dorritie Tags: 240 Source Type: research
Phase I Study of Bendamustine and Melphalan Conditioning Followed By Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma and B-Cell Lymphoma in Elderly Patients
High-dose chemo and autologous hematopoietic cell transplantation (AHCT) is an effective consolidation therapy in non-Hodgkin lymphoma (NHL) and multiple myeloma (MM); however, its use in elderly patients is limited by toxicity. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Gagan Raju, Gunjan L. Shah, Stephanie M. Lobaugh, Sean M. Devlin, Grashma Vadakkel, Stephen William Eng, Andrew Lin, Amethyst Saldia, Martin Donach, Danielle Engstler, Yetunde Aremu, Oscar B. Lahoud, Paul Hamlin, Michael Scordo, Miguel-Angel Perales, Crai Tags: 214 Source Type: research
Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy
As CAR-T treatment volumes increase, identifying optimal lymphodepleting chemotherapy (LDC) regimens is an urgent and unmet need. Fludarabine and cyclophosphamide (flu/cy) is most commonly used. However, an ongoing international fludarabine shortage has led to the adoption of bendamustine (benda). We performed a multi-center retrospective analysis on non-Hodgkin lymphoma (NHL) patients who received benda or flu/Cy LDC prior to infusion of FDA-approved CAR-T products across the Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Uttam Rao, Betsy Blunk, Carlos R. Bachier, Vikas Bhushan, Jose C Carlos Cruz, Mohammed M. Elayan, Ian W. Flinn, Tara Gregory, Dr. C. Fred LeMaistre, Navneet S. Majhail, Shahbaz Malik, Casey Martin, Gabrielle Blade, Michael Maris, John Mathews, Luke Mountj Tags: 70 Source Type: research
Cancers, Vol. 16, Pages 563: CT Images in Follicular Lymphoma: Changes after Treatment Are Predictive of Cardiac Toxicity in Patients Treated with Anthracycline-Based or R-B Regimens
o Postorino
Marcello Chiocchi
The aim of this study is to evaluate changes in epicardial adipose tissue (EAT) and cardiac extracellular volume (ECV) in patients with follicular lymphoma (FL) treated with R-CHOP-like regimens or R-bendamustine. We included 80 patients with FL between the ages of 60 and 80 and, using computed tomography (CT) performed at onset and at the end of treatment, we assessed changes in EAT by measuring tissue density at the level of the cardiac apex, anterior interventricular sulcus and posterior interventricular sulcus of the heart. EAT is known to be associated with metabolic syndrome, incre...
Source: Cancers - January 29, 2024 Category: Cancer & Oncology Authors: Fabiana Esposito Valeria Mezzanotte Cristiano Tesei Alessandra Luciano Paola Elda Gigliotti Andrea Nunzi Roberto Secchi Cecilia Angeloni Maria Pitaro Federico Meconi Martina Cerocchi Francesco Garaci Adriano Venditti Massimiliano Postorino Marcello Chiocc Tags: Article Source Type: research
Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine
(Source: Annals of Hematology)
Source: Annals of Hematology - December 29, 2023 Category: Hematology Source Type: research
A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
CONCLUSION: This study underscores the importance of considering patient characteristics before administering ibrutinib as salvage therapy. Early relapse was associated with poor outcomes, highlighting the need for novel therapeutic strategies.PMID:38151961 | DOI:10.5045/br.2023.2023208 (Source: Cell Research)
Source: Cell Research - December 28, 2023 Category: Cytology Authors: Yong-Pyo Lee Ye Ji Jung Junhun Cho Young Hyeh Ko Won Seog Kim Seok Jin Kim Sang Eun Yoon Source Type: research
A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
CONCLUSION: This study underscores the importance of considering patient characteristics before administering ibrutinib as salvage therapy. Early relapse was associated with poor outcomes, highlighting the need for novel therapeutic strategies.PMID:38151961 | DOI:10.5045/br.2023.2023208 (Source: Blood Research)
Source: Blood Research - December 28, 2023 Category: Hematology Authors: Yong-Pyo Lee Ye Ji Jung Junhun Cho Young Hyeh Ko Won Seog Kim Seok Jin Kim Sang Eun Yoon Source Type: research
A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
CONCLUSION: This study underscores the importance of considering patient characteristics before administering ibrutinib as salvage therapy. Early relapse was associated with poor outcomes, highlighting the need for novel therapeutic strategies.PMID:38151961 | DOI:10.5045/br.2023.2023208 (Source: Cell Research)
Source: Cell Research - December 28, 2023 Category: Cytology Authors: Yong-Pyo Lee Ye Ji Jung Junhun Cho Young Hyeh Ko Won Seog Kim Seok Jin Kim Sang Eun Yoon Source Type: research
A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
CONCLUSION: This study underscores the importance of considering patient characteristics before administering ibrutinib as salvage therapy. Early relapse was associated with poor outcomes, highlighting the need for novel therapeutic strategies.PMID:38151961 | DOI:10.5045/br.2023.2023208 (Source: Blood Research)
Source: Blood Research - December 28, 2023 Category: Hematology Authors: Yong-Pyo Lee Ye Ji Jung Junhun Cho Young Hyeh Ko Won Seog Kim Seok Jin Kim Sang Eun Yoon Source Type: research
